CD160 is a cell surface molecule expressed by most NK cells and approximately 50% of CD8+ cytotoxic T lymphocytes. Engagement of CD160 by MHC class-I directly triggers a costimulatory signal to TCR-induced proliferation, cytokine production and cytotoxic effector functions. The role of CD160 in alloimmunity is unknown. Using a newly generated CD160 fusion protein (CD160Ig) we examined the role of the novel costimulatory molecule CD160 in mediating CD4+ or CD8+ T cell driven allograft rejection. CD160Ig inhibits alloreactive CD8+ T cell proliferation and IFN-γ production in vitro, in particular in the absence of CD28 costimulation. Consequently CD160Ig prolongs fully mismatched cardiac allograft survival in CD4-/-, CD28-/- knockout and CTLA4Ig treated WT recipients, but not in WT or CD8-/- knockout recipients. The prolonged cardiac allograft survival is associated with reduced alloreactive CD8+ T cell proliferation, effector/memory responses and alloreactive IFN-γ production. Thus, CD160 signaling is particularly important in CD28-independent effector/memory CD8+ alloreactive T cell activation in vivo and therefore may serve as a novel target for prevention of allograft rejection.
CD160Ig Fusion Protein Targets a Novel Costimulatory Pathway and Prolongs Allograft Survival / F. D'Addio, T. Ueno, M. Clarkson, B. Zhu, A. Vergani, G.J. Freeman, M.H. Sayegh, M.J.I. Ansari, P. Fiorina, A. Habicht. - In: PLOS ONE. - ISSN 1932-6203. - 8:4(2013 Apr 04).
CD160Ig Fusion Protein Targets a Novel Costimulatory Pathway and Prolongs Allograft Survival
F. D'AddioPrimo
;P. FiorinaPenultimo
;
2013
Abstract
CD160 is a cell surface molecule expressed by most NK cells and approximately 50% of CD8+ cytotoxic T lymphocytes. Engagement of CD160 by MHC class-I directly triggers a costimulatory signal to TCR-induced proliferation, cytokine production and cytotoxic effector functions. The role of CD160 in alloimmunity is unknown. Using a newly generated CD160 fusion protein (CD160Ig) we examined the role of the novel costimulatory molecule CD160 in mediating CD4+ or CD8+ T cell driven allograft rejection. CD160Ig inhibits alloreactive CD8+ T cell proliferation and IFN-γ production in vitro, in particular in the absence of CD28 costimulation. Consequently CD160Ig prolongs fully mismatched cardiac allograft survival in CD4-/-, CD28-/- knockout and CTLA4Ig treated WT recipients, but not in WT or CD8-/- knockout recipients. The prolonged cardiac allograft survival is associated with reduced alloreactive CD8+ T cell proliferation, effector/memory responses and alloreactive IFN-γ production. Thus, CD160 signaling is particularly important in CD28-independent effector/memory CD8+ alloreactive T cell activation in vivo and therefore may serve as a novel target for prevention of allograft rejection.File | Dimensione | Formato | |
---|---|---|---|
CD160.pdf
accesso aperto
Descrizione: articolo principale
Tipologia:
Publisher's version/PDF
Dimensione
2.2 MB
Formato
Adobe PDF
|
2.2 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.